Omeros' Huntington's drug OMS824 gets FDA fast-track status

Omeros has received fast-track designation from the US Food and Drug Administration (FDA) for its phosphodiesterase 10 (PDE10) inhibitor 'OMS824' to treat cognitive impairment in patients with Huntington's disease.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news